CLAIMS

1. Use of a therapeutically effective amount of a T-type calcium channel antagonist in the manufacture of a medicament for the treatment of Dravet syndrome in a subject.

2. The use of claim 1, wherein the T-type calcium channel antagonist is a calcium channel antagonist that selectively targets T-type calcium channels.

3. The use of claim 1 or claim 2, wherein the T-type calcium channel antagonist is a small molecule, an antibody, or a siRNA.

4. The use of any one of claims 1 to 3, wherein the T-type calcium channel antagonist selectively targets $Ca_V3.1$, $Ca_V3.2$, and/or $Ca_V3.3$.

5. The use of any one of claims 1 to 4, wherein the T-type calcium channel antagonists antagonize a T-type calcium channel in a cell when the membrane potential of the cell is in the range from about -60 mV to about -30 mV, *e.g.*, about -40 mV.

6. The use of any one of claims 1 to 5, wherein said T-type calcium channel antagonist is selected from the group consisting of mibefradil, MK-8998, diltiazem, nifedipine, nitrendipine, nimodipine, niludipine, niguldipine, nicardipine, nisoldipine, amlodipine, felodipine, isradipine, ryosidine, gallopamil, verapamil, tiapamil, pimozide, thioridazine, NNC 55-0396, TTL-1177, anandamide, pimozide, penfluridol, clopimozide, fluspirilene, haloperidol, droperidol, benperidol, triperidol, melperone, lenperone, azaperone, domperidone, antrafenine, aripiprazole, ciprofloxacin, dapiprazole, dropropizine, etoperidone, itraconazole, ketoconazole, levodropropizine, mepiprazole, naftopidil, nefazodone, niaprazine, oxypertine, posaconazole, trazodone, urpidil, vesnarinone, manidipine, nilvadipine, benidipine, efonidipine, flunarizine, anandamide, lomerizine, zonisamide, U-92032, tetralol, mibefradil, NNC 55-0396, TTA-A2, TTA-A8, TTA-P1, 4-aminomethyl-4-fluoropiperidine (TTA-P2), TTA-Q3, TTA-Q6, MK-5395, MK-6526, MK-8998, Z941, Z944, phensuximide, mesuximide, desmethylmethsuximide, efonidipine, trimethadione, dimethadione, ABT-639, TTL-1177, KYSO5044, nickel, and kurtoxin, and combinations thereof.

7. The use of any one of claims 1 to 6, wherein the treatment comprises reducing or ameliorating at least one neurological symptom in the subject.

8. The use of claim 7, wherein the neurological symptom comprises one or more of seizure, hyperactivity, impulsiveness, autistic behavior, somnolence, insomnia, psychomotor delay, ataxia cognitive impairment, neurological development, developmental delay, and impaired behavior.

9. The use of any one of claims 1 to 8, wherein the treatment comprises reducing the frequency and/or severity of seizure in the subject.

10. The use of any one of claims 1 to 9, wherein the treatment comprises reducing the frequency and/or severity of hyperactivity in the subject.

11. The use of any one of claims 1 to 10, wherein the treatment comprises reducing the frequency and/or severity of impulsiveness in the subject.

12. The use of any one of claims 1 to 11, wherein the treatment comprises reducing the frequency and/or severity of autistic behavior in the subject.

13. The use of any one of claims 1 to 12, wherein the treatment comprises reducing the frequency and/or severity of somnolence in the subject.

14. The use of any one of claims 1 to 13, wherein the treatment comprises reducing the frequency and/or severity of insomnia in the subject.

15. The use of any one of claims 1 to 14, wherein the treatment comprises reducing the psychomotor delay of the subject.

16. The use of any one of claims 1 to 15, wherein the treatment comprises reducing the frequency and/or severity of ataxia in the subject.

17. The use of any one of claims 1 to 16, wherein the treatment comprises reducing the severity of cognitive impairment in the subject.

18. The use of any one of claims 1 to 17, wherein the treatment comprises improving the cognition of the subject.

19. The use of any one of claims 1 to 18, wherein the treatment comprises improving the memory of the subject.

20. The use of any one of claims 1 to 19, wherein the treatment comprises improving the neurological development of the subject.

21. The use of any one of claims 1 to 20, the treatment comprises reducing the developmental delay of the subject.

22. The use of any one of claims 1 to 21, wherein the treatment comprises reducing the frequency and/or severity of impaired behavior in the subject.

23. The use of any one of claims 1 to 22, wherein the treatment comprises prolonging survival in the subject.

24. The use of any one of claims 1 to 22, wherein said T-type calcium channel antagonist substantially crosses the blood brain barrier.

25. The use of any one of claims 1 to 22, wherein said T-type calcium channel antagonist does not substantially cross the blood brain barrier.

26. The use of any one of claims 1 to 25, further comprising administering to the subject an additional therapeutic agent.

27. The use of claim 26, wherein the additional therapeutic agent is an additional T-type calcium channel inhibitor.

28. The use of claim 26, wherein the additional therapeutic agent is an anticonvulsive agent.

29. The use of claim 28, wherein the anticonvulsive agent is selected from acetazolamide, clobazam, clonazepam, eslicarbazepine acetate, ethosuximide, lacosamide, levetiracetam, nitrazepam, oxcarbazepine, perampanel, piracetam, phenobarbital, pregabalin, primidone, retigabine, rufinamide, valproate, stiripentol, tiagabine, topiramate, vigabatrin, and zonisamide.

30. The use of any one of claims 1 to 29, further comprising administering an additional therapy selected from the group consisting of a ketogenic diet, physical therapy, occupational therapy, communication therapy, and behavioral therapy.